JP2008535848A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535848A5
JP2008535848A5 JP2008505559A JP2008505559A JP2008535848A5 JP 2008535848 A5 JP2008535848 A5 JP 2008535848A5 JP 2008505559 A JP2008505559 A JP 2008505559A JP 2008505559 A JP2008505559 A JP 2008505559A JP 2008535848 A5 JP2008535848 A5 JP 2008535848A5
Authority
JP
Japan
Prior art keywords
salt form
crystalline salt
crystalline
composition
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008505559A
Other languages
English (en)
Japanese (ja)
Other versions
JP5230407B2 (ja
JP2008535848A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/012978 external-priority patent/WO2006108127A2/en
Publication of JP2008535848A publication Critical patent/JP2008535848A/ja
Publication of JP2008535848A5 publication Critical patent/JP2008535848A5/ja
Application granted granted Critical
Publication of JP5230407B2 publication Critical patent/JP5230407B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008505559A 2005-04-06 2006-04-05 キノリン−カルボキサミド化合物の結晶形態物 Expired - Lifetime JP5230407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
US60/668,780 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012113464A Division JP2012153725A (ja) 2005-04-06 2012-05-17 キノリン−カルボキサミド化合物の結晶形態物

Publications (3)

Publication Number Publication Date
JP2008535848A JP2008535848A (ja) 2008-09-04
JP2008535848A5 true JP2008535848A5 (enExample) 2009-05-07
JP5230407B2 JP5230407B2 (ja) 2013-07-10

Family

ID=37074104

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008505559A Expired - Lifetime JP5230407B2 (ja) 2005-04-06 2006-04-05 キノリン−カルボキサミド化合物の結晶形態物
JP2012113464A Withdrawn JP2012153725A (ja) 2005-04-06 2012-05-17 キノリン−カルボキサミド化合物の結晶形態物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012113464A Withdrawn JP2012153725A (ja) 2005-04-06 2012-05-17 キノリン−カルボキサミド化合物の結晶形態物

Country Status (29)

Country Link
US (4) US7728004B2 (enExample)
EP (1) EP1874766B1 (enExample)
JP (2) JP5230407B2 (enExample)
KR (1) KR101322873B1 (enExample)
CN (1) CN101151264B (enExample)
AR (2) AR053208A1 (enExample)
AT (1) ATE479682T1 (enExample)
AU (1) AU2006232129B2 (enExample)
BR (1) BRPI0610657A2 (enExample)
CA (1) CA2603654C (enExample)
CY (1) CY1111275T1 (enExample)
DE (1) DE602006016586D1 (enExample)
DK (1) DK1874766T3 (enExample)
EA (1) EA012115B1 (enExample)
ES (1) ES2350495T3 (enExample)
HR (1) HRP20100629T1 (enExample)
IL (1) IL186023A (enExample)
MA (1) MA29403B1 (enExample)
MX (1) MX2007012438A (enExample)
MY (1) MY151075A (enExample)
NO (1) NO339699B1 (enExample)
NZ (1) NZ561900A (enExample)
PE (1) PE20061310A1 (enExample)
PL (1) PL1874766T3 (enExample)
PT (1) PT1874766E (enExample)
SI (1) SI1874766T1 (enExample)
TW (1) TWI377206B (enExample)
WO (1) WO2006108127A2 (enExample)
ZA (1) ZA200708071B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
DE602005016446D1 (de) * 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス， インコーポレーテッド 腸の前処置のための運動促進剤
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
HUE049642T2 (hu) * 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
LT2419104T (lt) 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CA3069989C (en) 2017-07-31 2025-05-06 Alfasigma S.P.A. METHODS FOR TREATING GASTROPARESIA SYMPTOMS USING VELUSETRAG
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
US20260124194A1 (en) 2022-09-20 2026-05-07 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE69113284T2 (de) * 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
WO1994012497A1 (fr) 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Compose heterocyclique
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
DE602005016446D1 (de) 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
US20060183901A1 (en) 2005-02-17 2006-08-17 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
BRPI0608392A2 (pt) 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Similar Documents

Publication Publication Date Title
CA2603654A1 (en) Crystalline hydrochloride salt of a quinolinone-carboxamide compound or a solvate thereof
TW201002682A (en) Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2010514807A5 (enExample)
TWI706949B (zh) (３-胺基-環氧丙-３-基甲基)-[２-(５,５-二氧-５,６,７,９-四氫-５入*６*-硫-８-氮雜-苯并環庚烯-８-基)-６-甲基-喹唑啉-４-基]-胺之新穎晶形
CN1575287A (zh) 乙酰替苯胺衍生物的α型或β型结晶
JP2018065876A (ja) ニロチニブと選択された共結晶体を含有する多成分結晶系
JP2014074067A (ja) メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形
JP2013541592A5 (enExample)
JP2010529986A5 (enExample)
BRPI0712299A2 (pt) Formulação de liberação modificada com um núcleo de comprimido; formulação de liberação modificada em multipartículas; cápsula compreendendo as multipartículas; embalagem laminada compreendendo as multipartículas; e método de tratamento da síndrome do intestino irritável em um mamífero necessitado.
CN102026994A (zh) 苯并咪唑化合物的晶体
JP2008546719A (ja) 結晶形のｏ−デスメチルベンラファキシン
US20250177418A1 (en) Neuroactive steroids for treatment of gastrointestinal diseases or conditions
CN105324375A (zh) 盐酸尼洛替尼的多晶型形式
WO2011050742A1 (zh) 阿戈美拉汀的新晶型及其制备方法
WO2011140816A1 (zh) 含腈基的噻吩并吡啶酯衍生物、其制备方法、应用和组合物
CN103068816B (zh) 酰胺化合物的结晶
JP2018536709A5 (ja) 脳神経の耳麻酔による疾患の治療用組成物
JP2008515907A5 (enExample)
JP2009517353A5 (enExample)
KR20150056565A (ko) 결정질 화합물
CN1443178A (zh) (r)－n－[5－甲基－8－(4－甲基哌嗪－1－基)－1,2,3,4－四氢－2－萘基]－4－吗啉代苯甲酰胺的新形态
JP2023518419A5 (enExample)
WO2008080290A1 (en) Selective m4 receptor antagonist and its medical use
JP2008530225A5 (enExample)